ACH-HYDROXYCHLOROQUINE SULFATE 200 MG
HYDROXYCHLOROQUINE SULFATE : 200 MG · DIN 02506696 · ACCORD HEALTHCARE INC
Health Canada status: APPROVED
What is ACH-HYDROXYCHLOROQUINE SULFATE?
ACH-HYDROXYCHLOROQUINE SULFATE 200 MG contains HYDROXYCHLOROQUINE SULFATE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02506696, held by ACCORD HEALTHCARE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 19-Oct-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02506696 |
|---|---|
| Brand name | ACH-HYDROXYCHLOROQUINE SULFATE |
| Generic / active ingredient | HYDROXYCHLOROQUINE SULFATE : 200 MG |
| Manufacturer | ACCORD HEALTHCARE INC |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | P01BA02 HYDROXYCHLOROQUINE |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 19-Oct-2020 |
What can be used instead?
Other Canadian products sharing ATC code P01BA02 HYDROXYCHLOROQUINE. 6 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-HYDROXYQUINE | 200 MG | TABLET | APOTEX INC | MARKETED | DIN 02246691 |
| HYDROXYCHLOROQUINE | 200 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02519348 |
| JAMP HYDROXYCHLOROQUINE SULFATE | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02491427 |
| MINT-HYDROXYCHLOROQUINE | 200 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02424991 |
| NRA-HYDROXYCHLOROQUINE | 200 MG | TABLET | NORA PHARMA INC | MARKETED | DIN 02511886 |
| PLAQUENIL | 200 MG | TABLET | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02017709 |
| AG-HYDROXYCHLOROQUINE | 200 MG | TABLET | ANGITA PHARMA INC. | APPROVED | DIN 02510863 |
| MYLAN-HYDROXYCHLOROQUINE | 200 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02252600 |
| NU-HYDROXYQUINE | 200 MG | TABLET | NU-PHARM INC | CANCELLED (UNRETURNED ANNUAL) | DIN 02335816 |
| PMS-HYDROXYCHLOROQUINE | 200 MG | TABLET | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02247113 |
Who else supplies HYDROXYCHLOROQUINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYDROXYCHLOROQUINE appears in 37 registered pack listings across 9 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.